EMA: Janssen-Cilag has Withdrew Extension Application for Velcade
Wall Street Journal
2, 2011, submitted an application to extend the marketing authorization for Velcade in combination with rituximab for the treatment of patients with relapsed follicular non-Hodgkin lymphoma. -At the time of the withdrawal, the application was under ...
Janssen withdraws attempt to extend Velcade indication in EU
J&J pulls file to extend Velcade's use in EU
Johnson & Johnson pulls EU submission for Velcade use in NHL